Chemokine receptor antagonism as a new therapy for multiple sclerosis

Bibliography

• WAKSMAN BH: Demyelinating disease: evolution of a paradigm. Neurochem. Res. (1999) 24:491–495.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY JH: Progress in determining the causes and treatment of multiple sclerosis. Nature (1999) 399:A40–47.
   PubMed Web of Science ®Google Scholar
• HOGANCAMP WE, RODRIGUEZ M, WEINSHENKER BG: Identification of multiple sclerosis-associated genes. Mayo Clin. Proc. (1997) 72:965–976.
   PubMed Web of Science ®Google Scholar
• OKSENBERG JR, HAUSER SL: New insights into the immunogenetics of multiple sclerosis. Curr. Opin. Neurol (1997) 10:181–185.
   PubMed Web of Science ®Google Scholar
• SADOVNICK AD, DYMENT D, EBERS GC: Genetic epidemiology of multiple sclerosis. Epidemiol. Rev. (1997) 19:99–106.
   PubMed Web of Science ®Google Scholar
• EBERS GC, DYMENT DA: Genetics of multiple sclerosis. Semin. Neurol. (1998) 18:295–299.
   PubMed Web of Science ®Google Scholar
• CHATAWAY J, FEAKES R, CORADDU F et al: The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain (1998) 121:1869–1887.
   PubMed Web of Science ®Google Scholar
• COMPSTON A: The genetic epidemiology of multiple sclerosis. Philos. Trans. R. Soc. Lond. B. Biol. ScL (1999) 354:1623–1634.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG: Epidemiology of multiple sclerosis. Neurol Clin. (1996) 14:291–308.
   PubMed Web of Science ®Google Scholar
• MARTINO G, HARTUNG HP: Immunopathogenesis of multiple sclerosis: the role of T-cells. Curr. Opin. Neurol. (1999) 12:309–321.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell (1996) 85:299–302.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, SIBLEY WA: Natural history and treatment of multiple sclerosis. Curr. Opin. Neurol. Neurosurg. (1992) 5:203–211.
   PubMedGoogle Scholar
• WEINSHENKER BG: Natural history of multiple sclerosis. Ann. Neurol. (1994) 36 (Suppl.):S6–S 11 .
   Google Scholar
• HAWKINS SA, MCDONNELL GV: Benign multiple sclerosis? Clinical course, long term follow up and assessment of prognostic factors [see comments]. J. Neurol Neurosurg. Psychiatry (1999) 67:148–152.
   PubMed Web of Science ®Google Scholar
• HICKEY WF: The pathology of multiple sclerosis: a historical perspective. J. Neuroimmunol. (1999) 98:37–44.
   PubMed Web of Science ®Google Scholar
• LASSMANN H, RAINE C, ANTEL J, PRINEAS J: Immunopa-thology of multiple sclerosis. J. Neuroimmunol. (1998) 86:213–218.
   PubMed Web of Science ®Google Scholar
• BITSCH A, WEGENER C, DA COSTA C et al.: Lesiondevelopment in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mull Scler. (1999) 5:138–146.
   Google Scholar
• KIESEIER BC, STORCH MK, ARCHELOS JJ, MARTINO G,HARTUNG HP: Effector pathways in immune mediated central nervous system demyelination. Curr. Opin. Neurol. (1999) 12:323–336.
   PubMed Web of Science ®Google Scholar
• KORNEK B, LASSMANN H: Axonal pathology in multiplesclerosis. A historical note. Brain Pathol. (1999) 9:651–656.
   PubMed Web of Science ®Google Scholar
• FERGUSON B, MATYSZAK MK, ESIRI MM, PERRY VH: Axonal damage in acute multiple sclerosis lesions. Brain (1997) 120:393–399.
   PubMed Web of Science ®Google Scholar
• MEWS I, BERGMANN M, BUNKOWSKI S, GULLOTTA F, BRUCK W: Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mull Scler. (1998) 4:55–62.
   PubMed Web of Science ®Google Scholar
• TRAPP B, PETERSON J, RANSOHOFF R et al.: Axonaltransection in the lesions of multiple sclerosis. N Engl. J. Med. (1998) 338:278–290.
   PubMed Web of Science ®Google Scholar
• SILBER E, SHARIEF MK: Axonal degeneration in thepathogenesis of multiple sclerosis. J. Neurol. Sci. (1999) 170:11–18.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JW, GEORGE EB, CHAUDHRY V: Wallerian degeneration in peripheral nerve disease. Baillieres Neurol. (1996) 5:65–75.
   PubMedGoogle Scholar
• GRIFFITHS I, KLUGMANN M, ANDERSON T et a/. :Axonalswellings and degeneration in mice lacking the major proteolipid of myelin. Science (1998) 280:1610–1613.
   Google Scholar
• WERNER H, JUNG M, KLUGMANN M et al.: Mouse modelsof myelin diseases. Brain Pathol (1998) 8:771–793.
   PubMed Web of Science ®Google Scholar
• WAXMAN SG: Demyelinating diseases-new pathological insights, new therapeutic targets. N Engl. J. Med. (1998) 338:323–325.
   PubMed Web of Science ®Google Scholar
• TRAPP BD, RANSOHOFF R, RUDICK R: Axonal pathologyin multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol (1999) 12:295–302.
   PubMed Web of Science ®Google Scholar
• SORENSEN TL, RANSOHOFF RM: Etiology and pathogenesis of multiple sclerosis. Semin. Neurol. (1998) 18:287–294.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI CF, BRUCK W, RODRIGUEZ M, LASSMANN H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. (1996) 6:259–274.
   PubMed Web of Science ®Google Scholar
• TIENARI PJ: Multiple sclerosis: multiple etiologies, multiple genes? Ann. Med. (1994) 26:259–269.
   Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, PARISI J et al: Quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain (1999) 122 (Pt. 12):2279–2295.
   Google Scholar
• RUDICK R, COOKFAIR D, SIMONIAN N et al.: Cerebro-spinal fluid abnormalities in a Phase III trial of avonex (IFNB-1a) for relapsing multiple sclerosis. J. Neurim-munol (1999) 93:8–15.
   PubMed Web of Science ®Google Scholar
• SIMON JH: From enhancing lesions to brain atrophy in relapsing MS. J. Neuroimmunol. (1999) 98:7–15.
   PubMed Web of Science ®Google Scholar
• ASENSIO VC, CAMPBELL IL: Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. (1999) 22:504–512.
   PubMed Web of Science ®Google Scholar
• VON ANDRIAN UH, CHAMBERS JD, MCENVOY LM et al.: Two-step model of leukocyte-endothelial cell interac-tion in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc. Natl. Acad. ScL USA (1991) 88:7538–7542.
   PubMed Web of Science ®Google Scholar
• BUTCHER E: Leukocyte-endothelial cell recognition: Three (or more) steps to specificty and diversity. Cell (1991) 67:1033–1036.
   PubMed Web of Science ®Google Scholar
• SCHALL TJ, BACON KB: Chemokines, leukocyte trafficking and inflammation. Curr. Opin. Immunol. (1994) 6:865–873.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Traffic signals for lymphocyte recircula-tion and leukocyte emigration: The multistep paradigm. Cell (1994) 76:301–314.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60–66.
   PubMed Web of Science ®Google Scholar
• BACON KB: Chemokines and chemokine receptors: Therapeutic targets in inflammation and infectious disease. Drug News Perspect. (1997) 10(3):133–143.
   Web of Science ®Google Scholar
• FOXMAN EF, CAMPBELL JJ, BUTCHER EC: Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. (1997) 139:1349–1360.
   PubMed Web of Science ®Google Scholar
• BAGGIOLINI M: Chemokines and leukocyte traffic.Nature (1998) 392:565–568.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JJ, HEDRICK J, ZLOTNIK A et al.: Chemokinesand the arrest of lymphocytes rolling under flow conditions. Science (1998) 279:381–384.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JJ, QIN S, BACON KB, MACKAY CR, BUTCHEREC: Biology of chemokine and classical chemoattrac-t ant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J. Cell Biol. (1996) 134:255–266.
   PubMed Web of Science ®Google Scholar
• MURPHY P: The molecular biology of leukocyte chemoattractant receptors. Ann. Rev. Immunol. (1994) 12:593–633.
   PubMed Web of Science ®Google Scholar
• KELVIN D, MICHIEL D, JOHNSTON J et al.: Chemokinesand serpentines: The molecular biology of chemokine receptors. J. Leukocyte Biol. (1993) 54:604–612.
   PubMed Web of Science ®Google Scholar
• HORUK R: Molecular properties of the chemokinereceptor family. Trends Pharmacol. Sci. (1994) 15:159–165.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM JJ, ZACHARIAE C, MUKAIDA N, MATSUSHIMA K: Properties of the novel proinflamma-tory supergene `intercrine' cytokine family. Ann. Rev. Immunol. (1991) 9:617–648.
   PubMed Web of Science ®Google Scholar
• TAUB DD, OPPENHEIM JJ: Chemokines, inflammationand the immune system. Ther. Immunol (1994) 1:229–246.
   PubMedGoogle Scholar
• ROLLINS BJ: Chemokines. Blood (1997) 90:908–928.
   Web of Science ®Google Scholar
• CYSTER JG: Chemokines and cell migration insecondary lymphoid organs. Science. (1999) 286:2098–2102.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, PALERMO B, LENIG D et al.: Distinctpatterns and kinetics of chemokine production regulate dendritic cell function. Eurj Immunol. (1999) 29:1617–1625.
   PubMed Web of Science ®Google Scholar
• BACON KB, OPPENHEIM JJ: Chemokines in disease models and pathogenesis. Cytokine Growth Factor Rev. (1998) 9:167–173.
   PubMed Web of Science ®Google Scholar
• BOLTON SJ, PERRY VH: Differential blood-brain barrierbreakdown and leucocyte recruitment following excitotoxic lesions in juvenile and adult rats. Exp. Neurol. (1998) 154:231–240.
   PubMed Web of Science ®Google Scholar
• PERRY VH, BOLTON SJ, ANTHONY DC, BETMOUNI S: Thecontribution of inflammation to acute and chronic neurodegeneration. Res. Immunol. (1998) 149:721–725.
   PubMedGoogle Scholar
• PERRY VH: A revised view of the central nervoussystem microenvironment and major histocompati-bility complex class II antigen presentation. J. Neuroimmunol. (1998) 90:113–121.
   PubMed Web of Science ®Google Scholar
• PERRY VH, ANTHONY DC, BOLTON SJ, BROWN HC: Theblood-brain barrier and the inflammatory response. Mol. Med. Today (1997) 3:335–341.
   PubMedGoogle Scholar
• CASTANO A, BELL MD, PERRY VH: Unusual aspects ofinflammation in the nervous system: Wallerian degeneration. Neurobiol. Aging (1996) 17:745–751.
   PubMed Web of Science ®Google Scholar
• PERRY VH, BELL MD, BROWN HC, MATYSZAK MK: Inflammation in the nervous system. Curr. Opin. Neurobiol (1995) 5:636–641.
   PubMed Web of Science ®Google Scholar
• LAWSON LJ, PERRY VH: The unique characteristics ofinflammatory responses in mouse brain are acquired during postnatal development. Eur. J. Neurosci. (1995) 7:1584–1595.
   PubMed Web of Science ®Google Scholar
• FABRY Z, RAINE C, HART M: Nervous tissue as animmune compartment: The dialect of the immune response in the CNS. Immunol. Today (1994) 15:218–224.
   PubMedGoogle Scholar
• SPERK G, LASSMANN H, BARAN H, KISH S, SEITELBERGERF: Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience (1983) 10:1301–1315.
   PubMed Web of Science ®Google Scholar
• BELL MD, PERRY VH: Adhesion molecule expression on murine cerebral endothelium following the injection of a proinflammagen or during acute neuronal degeneration. J. Neurocytol (1995) 24:695–710.
   PubMedGoogle Scholar
• POPOVICH P, WET P, STOKES B: Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp Neurol. (1997) 377:443–464.
   PubMed Web of Science ®Google Scholar
• MCTIGUE D, TANI M, KRAVACIC K et al.: Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J. Neurosci. Res. (1998) 53:368–376.
   PubMed Web of Science ®Google Scholar
• LIRA S, FUENTES M, STRIETER R, DURHAM S: Transgenic methods to study chemokine function in lung and central nervous system. Methods EnzymoL (1997) 287:304–318.
   PubMed Web of Science ®Google Scholar
• FUENTES M, DURHAM S, SWERDEL M et al: Controlled recruitment of monocytes/macrophages to specific organs via transgenic expression of MCP-1. J. Immunol. (1995) 155:5769–5776.
   PubMed Web of Science ®Google Scholar
• TANI M, FUENTES ME, PETERSON JW et al.: Neutrophil infiltration, glial reaction and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. j Clin. Invest. (1996) 98:529–539.
   PubMed Web of Science ®Google Scholar
• BELL MD, TAUB DD, KUNKEL SJ et al.: Recombinant human adenovirus with rat MIP-2 gene insertion causes prolonged PMN recruitment to the murine brain. Eur.J. Neurosci. (1996) 8:1803–1811.
   PubMed Web of Science ®Google Scholar
• BELL MD, TAUB DD, PERRY VH: Overriding the brain'sintrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience (1996) 74:283–292.
   PubMed Web of Science ®Google Scholar
• HUFFNAGLE GB, MCNEIL LK: Dissemination of C.neoformans to the central nervous system: role of chemokines, Thl immunity and leukocyte recruit-ment../. Neurovirol (1999) 5:76–81.
   Google Scholar
• DAL CANTO M, MELVOLD R, KIM B, MILLER S: Two models of multiple sclerosis: Experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Micros-copy Res. Technique (1995) 32:215–229.
   PubMed Web of Science ®Google Scholar
• RAINE CS: Analysis of autoimmune demyelination: itsimpact upon multiple sclerosis. Lab. Invest. (1984) 50:608–635.
   PubMed Web of Science ®Google Scholar
• ENG LF, GHIRNIKAR RS, LEE YL: Inflammation in EAE: role of chemokine/cytokine expression by resident and infiltrating cells. Neurochem. Res. (1996) 21:511–525.
   PubMed Web of Science ®Google Scholar
• BROSNAN CF, RAINE CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol. (1996) 6:243–257.
   PubMed Web of Science ®Google Scholar
• TSUNODA I, FUJINAMI RS: Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J. Neuropathol. Exp. Neurol. (1996) 55:673–686.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: A few autoreactive cells in an autoim-mune infiltrate control a vast population of nonspe-cific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. USA (1996) 93:2253–2256.
   PubMed Web of Science ®Google Scholar
• STEINMAN L, MILLER A, BERNARD CC, OKSENBERG JR: The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy. Ann. Rev. Neurosci. (1994) 17:247–265.
   PubMed Web of Science ®Google Scholar
• RANSOHOFF RM, HAMILTON TA, TANI M et al.: Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalo-myelitis. FASEB J (1993) 7:592–602.
   PubMed Web of Science ®Google Scholar
• HULKOWER K, BROSNAN CF, AQUINO DA et al.: Expres-sion of CSF-1, c-fms and MCP-1 in the central nervous system of rats with experimental allergic encephalo-myelitis. J. Immunol. (1993) 150:2525–2533.
   PubMed Web of Science ®Google Scholar
• GODISKA R, CHANTRY D, DIETSCH GN, GRAY PW: Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. (1995) 58:167–176.
   PubMed Web of Science ®Google Scholar
• KARPUS WJ, LUKACS NW, MCRAE BLet al.: An importantrole for the chemokine macrophage inflammatory protein-1 a in the pathogenesis of the T-cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. (1995) 155:5003–5010.
   Google Scholar
• KENNEDY KJ, STRIETER RM, KUNKEL SL, LUKACS NW,KARPUS WJ: Acute and relapsing experimental autoim-mune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflam-matory protein-lalpha and monocyte chemotactic protein-1. J. Neuroimmunol. (1998) 92:98–108.
   PubMed Web of Science ®Google Scholar
• MIYAGISHI R, KIKUCHI S, TAKAYAMA C, INOUE Y, TASHIRO K: Identification of cell types producing RANTES, MIP-1 a and MIP-113 in rat experimental autoimmune encephalomyelitis by in situ hybridiza-tion. J. Neuroimmunol. (1997) 77:17–26.
   PubMed Web of Science ®Google Scholar
• GLABINSKI A, TANI M, STRIETER R, TUOHY V,RANSOHOFF R: Synchronous synthesis of a - and 13 -chemokines by cells of diverse lineage in the central nervous system of mice with relapses of experimental autoimmune encephalomyelitis. Am. J. Pathol (1997) 150:617–630.
   PubMed Web of Science ®Google Scholar
• RANSOHOFF RM, GLABINSKI A, TANI M: Chemokines inimmune-mediated inflammation of the central nervous system. Cytokine Growth Factor Rev. (1996) 7:35–46.
   PubMedGoogle Scholar
• TANI M, GLABINSKI AR, TUOHY VK et al: In situ hybridi-zation analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalo-myelitis. Am. J. Pathol. (1996) 148:889–896.
   PubMed Web of Science ®Google Scholar
• GLABINSKI A, TANI M, TUOHY VK, TUTHILL R,RANSOHOFF RM: Central nervous system chemokine gene expression follows leukocyte entry in acute murine experimental autoimmune encephalomye-litis. Brain Behav. Immunol. (1996) 9:315–330.
   Web of Science ®Google Scholar
• GLABINSKI AR, TUOHY VK, RANSOHOFF RM: Expres-sion of chemokines RANTES, MIP-lalpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation (1998) 5:166–171.
   PubMed Web of Science ®Google Scholar
• HICKEY WF: Migration of haematogenous cellsthrough the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. (1991) 1:97–105.
   PubMed Web of Science ®Google Scholar
• HICKEY WF, HSU BL, KIMURA H: T-lymphocyte entryinto the central nervous system. J. NeuroscL Res. (1991) 28:254–260.
   PubMed Web of Science ®Google Scholar
• JIANG Y, SALAFRANCA MN, ADHIKARI S et al.: Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J. Neuroimmunol. (1998) 86:1–12.
   PubMed Web of Science ®Google Scholar
• BACON KB, HARRISON JK: Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J. Neuroimmunol. (2000) 104:92–97.
   PubMed Web of Science ®Google Scholar
• HAYASHI M, LUO Y, LANING J, STRIETER RM, DORF ME:Production and function of monocyte chemoattrac-tant protein-1 and other beta-chemokines in murine glial cells. J. Neuroimmunol. (1995) 60:143–150.
   PubMed Web of Science ®Google Scholar
• MAJUMDER S, ZHOU LZ, RANSOHOFF RM: Transcrip-tional regulation of chemokine gene expression in astrocytes. j Neurosci. Res. (1996) 45:758–769.
   PubMed Web of Science ®Google Scholar
• GLABINSKI AR, KRAKOWSKI M, HAN Y, OWENS T, RANSOHOFF RM: Chemokine expression in GKO mice (lacking interferon-gamma) with experimental autoimmune encephalomyelitis. J. Neurovirol. (1999) 5:95–101.
   PubMed Web of Science ®Google Scholar
• LUSTER AD, UNKELESS JC, RAVETCH JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature (1985) 315:672–676.
   PubMed Web of Science ®Google Scholar
• FITEN P, VANDENBROECK K, DUBOIS B eta]: Microsatel-lite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J. Neuroimmunol. (1999) 95:195–201.
   PubMed Web of Science ®Google Scholar
• BENNETTS BH, TEUTSCH SM, BUHLER MM, HEARD RN, STEWART GJ: The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. (1997) 58:52–59.
   PubMed Web of Science ®Google Scholar
• SELLEBJERG F. CCR5 delta 32, matrix metallo proteinase-9 and disease activity in multiple sclerosis. Neuroimmunol. (2000) 102(0:98–106.
   Google Scholar
• BARCELLOS L, SCHITO A, RIMMLER Jet al CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics (2000) (In press)
   Google Scholar
• TEUSCHER C, BUTTERFIELD RJ, MA RZ et al: Sequence polymorphisms in the chemokines Scyal (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1) and Scyal2 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J. Immunol. (1999) 163:2262–2266.
   PubMed Web of Science ®Google Scholar
• CANANZI AR, FERRO-MILONE F, GRIGOLETTO F et al: Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis. Acta Neurol Scand. (1987) 76:79–85.
   PubMed Web of Science ®Google Scholar
• MIYAGISHI R, KIKUCHI S, FUKAZAWA T, TASHIRO K: Macrophage inflammatory protein-1 a in the cerebro-spinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol ScL (1995) 129:223–227.
   PubMed Web of Science ®Google Scholar
• SORENSEN T, TANI M, JENSEN J et al.: Expression of specific chemokines and chemokine receptors in the central nervous system of mutiple sclerosis patients. J. Clin. Invest. (1999) 106:807–815.
   Web of Science ®Google Scholar
• BALASHOV KE, ROTTMAN JB, WEINER HL, HANCOCK WW: CCR5(+) and CXCR3(+) T-cells are increased in multiple sclerosis and their ligands MIP-lalpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. ScL USA (1999) 96:6873–6878.
   PubMed Web of Science ®Google Scholar
• STRUNK T, BUBEL S, MASCHER B et al.: Increased numbers of CCR5+ interferon-y - and tumor necrosis factor- a -secreting T lymphocytes in multiple sclerosis patients. Ann. Neurol. (2000) 47:269–273.
   PubMed Web of Science ®Google Scholar
• MCMANUS C, BERMAN JW, BRETT FM et al.: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridi-zation study. J. Neuroimmunol. (1998) 86:20–29.
   PubMed Web of Science ®Google Scholar
• SIMPSON J, NEWCOMBE J, CUZNER M, WOODROOFE M: Expression of monocyte chemoattractant protein-1 and other 13 -chemokines by resident and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. (1998) 84:238–249.
   PubMed Web of Science ®Google Scholar
• VAN DER VOORN P, TEKSTRA J, BEELEN RH et al.: Expres-sion of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathoi (1999) 154:45–51.
   Google Scholar
• HVAS J, MCLEAN C, JUSTESEN J et al: Perivascular T-cells express the proinflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand. J. Immunol. (1997) 46:195–203.
   PubMed Web of Science ®Google Scholar
• KIVISAKK P, TELESHOVA N, OZENCI V et al.: No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J. Neuroimmunol. (1998) 91:108–112.
   PubMed Web of Science ®Google Scholar
• GODISKA R, CHANTRY D, DIETSCH G, GRAY P: Chemokine expression in murine experimental autoimmune encephalomyelitis. J. Leukocyte Biol. (1994) Supplement: 17 (Abstract).
   Google Scholar
• MIYAGISHI R, KIKUCHI S, TAKAYAMA C, INOUE Y, TASHIRO K: Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experi-mental autoimmune encephalomyelitis by in situ hybridization. J. Neuroimmunol. (1997) 77:17–26.
   PubMed Web of Science ®Google Scholar
• BERMAN J, GUIDA M, WARREN J, AMAT J, BROSNAN C: Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experi-mental autoimmune encephalomyelitis and trauma in the rat. J. Immunol. (1996) 156:3017–3023.
   PubMed Web of Science ®Google Scholar
• PONATH PD: Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. Exp. Opin. Invest. Drugs (1998) 1:1–18.
   Google Scholar
• NG HP, MAY K, BAUMAN JG et al: Discovery of novel non-peptide CCR1 receptor antagonists. (1999) J. Med. Chem. 42: 4680–4694.
   Google Scholar
• BABA M, NISHIMURA O, KANZAKI N et al. A small molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. (1999) Proc. Nati Acad. Sci. USA 96:5698–5703.
   Google Scholar